

ORIGINAL ARTICLE

Lung function response and side effects to rapamycin for lymphangioliomyomatosis: a prospective national cohort study

Janet Bee,¹ Sharon Fuller,¹ Suzanne Miller,² Simon R Johnson^{1,2}

¹National Centre for Lymphangioliomyomatosis, Nottingham, UK
²Division of Respiratory Medicine, Nottingham Molecular Pathology Node and Nottingham Biomedical Research Centre, University of Nottingham, Nottingham, UK

Correspondence to

Professor Simon R Johnson, Division of Respiratory Medicine, University of Nottingham, Respiratory Medicine, Queens Medical Centre, Nottingham NG7 2UH, UK; simon.johnson@nottingham.ac.uk

Received 7 August 2017
 Revised 19 September 2017
 Accepted 2 October 2017
 Published Online First 9 October 2017

ABSTRACT

Rationale Mechanistic target of rapamycin inhibitors reduce loss of lung function in lymphangioliomyomatosis (LAM), although their benefit varies between individuals. We examined lung function response and side effects to rapamycin in a national cohort.

Methods Subjects were receiving rapamycin for progressive lung disease. Clinical evaluation, detailed phenotyping, serial lung function, rapamycin and safety monitoring were performed according to a clinical protocol. Lung function change, measured as FEV₁ slope (Δ FEV₁), was reported for those treated for 1 year or longer.

Results Rapamycin was associated with improved Δ FEV₁ in 21 individuals where pretreatment data were available ($p < 0.0001$). In 47 treated for a mean duration of 35.8 months, mean Δ FEV₁ was +11 (SD 75) mL/year, although it varied from +254 to -148 mL/year. The quartile with the highest positive Δ FEV₁ had greater pretreatment FEV₁ ($p = 0.02$) and shorter disease durations ($p = 0.02$) than the lowest quartile. Serum rapamycin level was positively associated with side effects ($p = 0.02$) but not Δ FEV₁ over 1 year. Within the first month of therapy, aphthous ulcers, nausea and diarrhoea were associated with higher rapamycin levels. Acne, oedema and menstrual irregularities tended to increase over the first year of therapy. At the end of observation, the prevalence of side effects was 5% or less.

Conclusions Rapamycin reduces lung function loss in LAM, although in some, Δ FEV₁ continues to fall at an accelerated rate. Poor response to rapamycin was associated with lower pretreatment lung function and longer disease duration but not serum level. Early intervention with low-dose rapamycin may preserve lung function and reduce side effects.

INTRODUCTION

Lymphangioliomyomatosis (LAM) is a multisystem disease characterised by lung cysts, lymphatic abnormalities and a high prevalence of kidney angiomyolipomas.¹ As a sporadic disease, LAM affects almost exclusively women with an incidence of 0.3 per million women per year: however, LAM is common in the autosomal genetic disease tuberous sclerosis complex (TSC-LAM) where it affects around half of adult women and some men.² In LAM, cysts replace the lung parenchyma, resulting in recurrent pneumothorax and dyspnoea, which

Key messages

What is the key question?

- ▶ How can we best optimise the risk–benefit balance of mechanistic target of rapamycin (mTOR) inhibition for loss of lung function in individuals with lymphangioliomyomatosis (LAM)?

What is the bottom line?

- ▶ Loss of lung function may continue in some individuals treated with rapamycin, and a poor response to the drug is more likely in those with lower lung function and longer disease duration at the start of treatment. Lower levels of rapamycin are associated with fewer side effects but equal benefit compared with higher levels.

Why read on?

- ▶ We have used a prospective national cohort study to understand the relationship between rapamycin levels, lung function response and side effects to improve the use of mTOR inhibitors in women with LAM.

can progress over a variable period of years to result in respiratory failure. Lymphatic involvement can cause lymphatic masses and chylous collections in the thorax and abdomen. Angiomyolipomas are frequently small and asymptomatic but may enlarge and bleed, necessitating urgent treatment.

The lungs and lymphatics of women with LAM are infiltrated by LAM cells: a clone of cells expressing markers of both melanogenesis and smooth muscle differentiation. LAM cells in both sporadic and TSC-LAM have bi-allelic inactivating mutations in either the TSC-1 or more frequently the TSC-2 gene.³ Loss of function of TSC-1/2 leads to constitutive activation of the mechanistic target of rapamycin (mTOR), resulting in altered translation of 5' cap-dependent genes, uncontrolled proliferation, dependence on autophagy and a metabolic shift toward energy generation by glycolysis.⁴ Suppression of mTOR signalling in women with LAM is associated with reduced loss of lung function,^{5–7} reduction in angiomyolipoma volume^{8–10} and reduced chylous complications.¹¹ The use of mTOR inhibitors has become the standard of care for progressive lung disease in sporadic LAM¹² and



▶ <http://dx.doi.org/10.1136/thoraxjnl-2017-211135>



To cite: Bee J, Fuller S, Miller S, et al. *Thorax* 2018;**73**:369–375.

in TSC for LAM, angiomyolipoma and subependymal giant cell astrocytoma.¹³

Although mTOR inhibitors reduce the rate of loss of FEV₁ in those with progressive disease, some of those treated continue to decline, and it is not clear how to manage these individuals.^{14 15} Further, mTOR inhibition is associated with oral mucositis, nausea, diarrhoea, oedema, acne, hyperlipidaemia, proteinuria, pneumonitis and a theoretical risk of future malignancy.¹⁴ As many women with LAM develop progressive disease in their 30s, the potential cumulative exposure to mTOR inhibitors over decades means that the risk of adverse effects is significant. Although data from clinical trials and selected populations have reported clinical response and side effects,^{7 16} how these are related to drug levels has not been examined. As LAM is an orphan disease with no surrogate markers of disease activity, performing conventional randomised studies to understand different treatment regimens requires international collaborations over many years at potentially prohibitive cost. To address how to best preserve lung function, limit side effects from mTOR inhibition and inform future clinical trial design, we used a prospective national cohort study of women with LAM treated with rapamycin for progressive lung disease over a period of 1–6 years study to examine the relationship between lung function response, side effect profile and clinical features.

METHODS

The study was conducted at the National Centre for Lymphangi-oleiomyomatosis at Nottingham University Hospitals NHS Trust between 2011 and 2017. The Centre is funded by highly specialised commissioning for NHS England to provide a comprehensive clinical service for women with LAM in the UK. Women receiving care at the LAM Centre are invited to participate in an observational cohort study. All participants gave written informed consent.

The diagnosis of LAM was made according to American Thoracic Society (ATS) criteria.¹² Clinical history, lung function, imaging and blood samples were collected at recruitment. Duration of disease was calculated as the interval between the first symptom attributable to LAM (eg, first pneumothorax or onset of dyspnoea) and the start of treatment with rapamycin.

All subjects had progressive lung disease. The decision to start rapamycin was made on clinical grounds alone. Subjects were treated according to a standard clinical protocol: individuals had baseline full blood count, urea and electrolytes, liver function tests, lipid profile, urine protein:creatinine ratio (PCR) and a pregnancy test. All were counselled on the indication for treatment, need for monitoring, potential adverse effects and drug interactions. Advice was given around intercurrent illness, surgery, pregnancy and supported with written information. All were given contact details of the Centre nurse specialist for queries and advice.

Rapamycin, generally 1 or 2 mg orally once daily, was prescribed and a trough level measured 10–14 days later. One month later, subjects returned for a clinical assessment of side effects, a trough rapamycin level, full blood count, urea and electrolytes, liver function tests, lipid profile and urine PCR and the dose adjusted on the basis of serum level or side effects if required. After 3 months, these tests were repeated and FEV₁ and DL_{CO} measured. This assessment was repeated at 6 months of treatment and every 6 months thereafter. Subjects saw both a consultant physician (SJ) and nurse specialist (SF) at each visit, and side effects were recorded.

Lung function was measured according to ATS/European Respiratory Society standards¹⁷ with predicted values calculated using regression equations from Quanjer *et al.*¹⁸ Change in FEV₁ over time (Δ FEV₁) was calculated as the regression slope of all FEV₁ measurements taken either before rapamycin or during treatment using Microsoft Excel as described.^{15 19} As shorter periods of observation and fewer individual measurements are associated with variation away from the group mean for Δ FEV₁ in those with LAM,¹⁹ Δ FEV₁ was only reported for periods of observation of 1 year or greater. Serum vascular endothelial growth factor-D (VEGF-D) was measured using a human quantikine VEGF-D ELISA (R&D Systems, UK). Serum cholesterol, urea and electrolytes, full blood count, liver function and urine PCR were measured in the clinical service laboratory at Nottingham University NHS Trust.

Data were analysed in GraphPad Prism V.7.03 (GraphPad Software, La Jolla, California, USA), MS Excel and SPSS V.24 (IBM). Data were tested for normality using the D'Agostino-Pearson test. Paired Δ FEV₁ values before and after therapy were compared by paired Student's t-test, comparison of cholesterol and PCR before and after treatment by paired Student's t-test for the individual subjects, non-parametric data by Fischer's exact and χ^2 tests and association of rapamycin level with side effects and laboratory markers by Pearson correlation. Student's t-tests were reported uncorrected unless stated. Comparison of pretreatment disease duration and lung function, drug level and phenotype characteristics with Δ FEV₁ was performed for the quartiles with the best and poorest response to rapamycin by unpaired Student's t-tests and for the group as a whole by multivariable analysis. p Values of <0.05 were considered significant.

RESULTS

Study cohort

Forty-seven women with definite LAM defined by ATS criteria and progressive lung disease who had been treated with rapamycin for longer than 1 year were included in the study. The mean age at the start of treatment was 43.6 (SD 8.2) years and the mean duration of treatment was 35.8 (SD 18) months equating to 143 patient/years of treatment observation. Mean pretreatment FEV₁ was 52% (19) and DL_{CO} 42% (12) of the predicted values. Nine (19%) had TSC, 18 (38%) had a history of pneumothorax, angiomyolipoma was present in 9 (19%) and lymphatic complications, defined as chylous collections or lymphatic masses visible on CT scanning, were also present in 9 (19%) individuals.

Effect of rapamycin on Δ FEV₁

Twenty-one of the 47 individuals also had more than 1 year of observation of lung function prior to treatment with rapamycin. The remaining 26 had been treated elsewhere or required treatment at diagnosis and pretreatment data were not available. There was no significant difference in age, baseline lung function or response lung function response to rapamycin within those with and without pretreatment data. Within these 21, the mean duration of observation was 38 (SD 22) and 36 (SD 20) months pretreatment and post-treatment, respectively. Mean pretreatment Δ FEV₁ was -150 mL/year (95% CI -220 to -79) and during treatment was $+35$ mL/year (95% CI $+9$ to $+61$, $p < 0.0001$). Furthermore, loss of FEV₁ improved during rapamycin treatment in all individuals (figure 1A).

For all 47 subjects, mean treatment Δ FEV₁ was $+11$ (SD 75) mL/year, although between individuals, Δ FEV₁ varied from $+254$ to -148 mL/year. To understand the characteristics associated with




Figure 1 Change in FEV₁ in response to rapamycin. (A) Loss of FEV₁ (Δ FEV₁) in individuals prior to and during treatment with rapamycin. Δ FEV₁ improved in all of those treated and was significant in the group as a whole. (B) Variation in Δ FEV₁ between 47 individuals treated with rapamycin. (C) Lung function response to rapamycin (Δ FEV₁) is not related to mean serum rapamycin level over one year. (D) Relationship between Δ FEV₁ and duration of rapamycin treatment. Outlying values of Δ FEV₁ tend to be associated with shorter durations of observation.

differing responses to rapamycin, subjects were analysed in two ways. First, subjects were divided into quartiles according to their treatment Δ FEV₁ (figure 1B). The 25% of those with the highest positive Δ FEV₁ when treated with rapamycin (quartile 1) had significantly higher pretreatment FEV₁ and shorter disease duration than the 25% of those with the lowest negative Δ FEV₁ (quartile 4). There was no significant association with serum rapamycin level (figure 1C), the presence of angiomyolipoma, pneumothorax or lymphatic complications (table 1). Those with the highest or lowest values of Δ FEV₁ tended to have periods of observation of less than 3 years (figure 1D). Next, the relationship between Δ FEV₁ and pretreatment disease duration, pretreatment FEV₁ and DL_{CO} was subjected to multivariate analysis for all subjects. In initial univariate analyses, disease duration (unadjusted $p=0.02$) and baseline FEV₁ (unadjusted $p=0.006$) were associated with treatment response, although baseline DL_{CO} was not (unadjusted $p=0.33$). Neither disease duration nor baseline FEV₁ remained significant in a subsequent multivariate analysis.

To determine if the lack of association between serum rapamycin levels and treatment response was due to maintaining higher serum drug levels in those with more severe disease, we examined the association between rapamycin level and baseline lung function. There was a slight negative correlation between rapamycin level over 1 year and baseline FEV₁ ($r=-0.37$ (95% CI -0.62 to -0.048), $p=0.026$) but not DL_{CO} ($r=-0.28$ (95% CI -0.56 to 0.054), $p=0.099$).

Side effects of rapamycin

Due to follow-up schedules, intercurrent illness and travel issues to the LAM centre, 11 subjects had some missing values for rapamycin levels or side effects, and these subjects were excluded from the side effect profile analysis. Most individuals experienced side effects, which required a dose reduction in 25% of cases, although all continued with treatment. The most common side effects were aphthous ulcers, nausea, acne, oedema and menstrual irregularities (table 2). Within the first month of therapy,

Table 1 Clinical characteristics of quartiles of Δ FEV₁ response to rapamycin

| Δ FEV ₁ response quartile | Q1 | Q2 | Q3 | Q4 | Q1 vs Q4 (p) |
|---|------------|-------------|-----------|-------------|--------------|
| n | 11 | 12 | 12 | 12 | |
| Rapamycin-treated ΔFEV₁ | | | | | |
| Range (mL/year) | 254 to 56 | 50 to 0 | -1 to -30 | -31 to -148 | - |
| Mean (mL/year) | 111 (58) | 28 (15) | -17 (11) | -71 (41) | <0.0001 |
| Duration of treatment (years) | 2.4 (1.3) | 3.4 (1.6) | 2.8 (1.1) | 2.4 (2.1) | 0.09 |
| Clinical characteristics at start of treatment | | | | | |
| Pretreatment Δ FEV ₁ (mL/year)* | -186 (238) | -100 (69) | -152 (77) | -53 (202) | 0.20 |
| Age (years) | 41 (9) | 45 (11) | 44 (8) | 45 (6) | 0.13 |
| Disease duration (years) | 6.1 (5.3) | 13.0 (10.2) | 8.2 (5.0) | 11.3 (5.9) | 0.02 |
| FEV ₁ (% predicted) | 67 (23) | 42 (10) | 52 (17) | 48 (20) | 0.02 |
| DL _{CO} (% predicted) | 46 (11) | 40 (10) | 45 (14) | 40 (15) | 0.13 |
| Disease features present | | | | | |
| Angiomyolipoma | 6 | 5 | 6 | 3 | NS |
| Lymphatic disease | 3 | 3 | 1 | 2 | NS |
| TSC | 3 | 2 | 2 | 2 | NS |
| Ever had pneumothorax | 5 | 4 | 6 | 3 | NS |
| Post-treatment laboratory values | | | | | |
| Trough rapamycin level (ng/mL)† | 4.2 (1.2) | 5.2 (1.2) | 5.6 (1.7) | 5.2 (1.5) | 0.07 |
| Urine protein:creatinine ratio‡ | 8 (5-366) | 9 (6-43) | 11 (5-79) | 8 (6-15) | 0.84 |

*For 21 subjects only.

†Mean value over 12 months (p for Student's t-test).

‡Median (range) value after 12 months (p for Mann-Whitney test). NS for non-parametric data analysed by χ^2 and Fischer's exact test.**Table 2** Side effects experienced while taking rapamycin according to duration of treatment and categorised by the Common Terminology Criteria for Adverse Events

| Treatment duration (months) | % affected | | | | |
|--|------------|----|----|--------|------|
| | 1 | 6 | 12 | Latest | Ever |
| Common Terminology Criteria for Adverse Events Category | | | | | |
| Gastrointestinal | | | | | |
| Oral mucositis | 58 | 35 | 24 | 13 | 65 |
| Diarrhoea | 32 | 12 | 10 | 0 | 41 |
| Nausea | 24 | 3 | 5 | 0 | 24 |
| Abdominal pain | 6 | 0 | 0 | 0 | 6 |
| Indigestion | 6 | 0 | 0 | 0 | 6 |
| Bloating | 0 | 3 | 5 | 6 | 9 |
| Reflux symptoms | 0 | 0 | 0 | 5 | 5 |
| Dermatological | | | | | |
| Acne | 6 | 17 | 18 | 0 | 41 |
| Rash | 3 | 10 | 0 | 0 | 12 |
| Dry skin | 6 | 0 | 0 | 0 | 6 |
| Soft tissues | | | | | |
| Periphereal oedema | 5 | 7 | 0 | 0 | 9 |
| Sexual or reproductive function | | | | | |
| Menstrual cycle disturbances | 0 | 7 | 5 | 0 | 15 |
| Constitutional symptoms | | | | | |
| Fatigue | 3 | 7 | 0 | 5 | 9 |
| Infection | | | | | |
| Upper respiratory/bronchitis | 12 | 24 | 10 | 13 | 35 |
| Tonsillitis | 3 | 7 | 0 | 0 | 6 |
| Pneumonia | 0 | 3 | 0 | 5 | 5 |
| Urinary tract infection | 0 | 7 | 0 | 0 | 6 |
| Skin infection | 3 | 7 | 0 | 0 | 9 |
| Musculoskeletal | | | | | |
| Arthralgia or myalgia | 3 | 3 | 5 | 0 | 6 |

apthous ulcers, nausea and diarrhoea were most common. These fell from 59%, 32% and 24% after 1 month to 15%, 7% and 2%, respectively, after 1 year of therapy (figure 2A). The incidence of acne, oedema and menstrual irregularities tended to increase over the first year of therapy from 7%, 5% and 0%, respectively, at 1 month to 17%, 12% and 7% of individuals, respectively, at 12 months. By the end of the observation period (mean treatment duration of 35.8 months), the prevalence of all side effects was 5% or less in all those treated. Pneumonitis was not observed at any time.

Relationship between side effects and rapamycin level

We next examined the association between serum rapamycin level and the six most common side effects over the first month and first 12 months of treatment. After 1 month, 40% of those with a rapamycin level <3 pg/mL developed apthous ulcers but none of the other six common side effects. During the first month of treatment, apthous ulcers and diarrhoea were associated with increasing rapamycin levels (figure 2B). An increasing incidence of apthous ulcers and diarrhoea was also associated with higher mean serum rapamycin levels over 1 year, as were nausea, acne and menstrual irregularities (figure 2C). While the prevalence of individual side effects for differing rapamycin levels did not allow statistical analysis, the total occurrence of the six major side effects was positively correlated with mean rapamycin level over 1 year ($r=0.39$, $p=0.02$).

Effect of rapamycin on laboratory values

Treatment with rapamycin was associated with a significant elevation of serum cholesterol within the first month of treatment from a baseline of 5.1 mmol/L (95% CI 4.8 to 5.4) to 5.6 (95% CI 5.2 to 6.0), which was sustained for the whole




Figure 2 Side effects of rapamycin treatment. (A) Relationship between side effects and treatment duration. Colours of markers and side effects are consistent in subsequent figures. (B) Side effects according to rapamycin level after 1 month of therapy. (C) Side effects according to rapamycin level after 1 year.

duration of treatment (figure 3A). Urinary PCR was variable between individuals, and although there was a trend toward an increase PCR over the first year of treatment, this returned to pretreatment values over the course of treatment (mean duration 35 months; figure 3A). There were no significant changes in haemoglobin and renal or liver function over the treatment period (data not shown).

Although those with higher plasma rapamycin levels tended to have the larger elevations of serum cholesterol, the serum level of rapamycin over 12 months of treatment was not significantly related to the increase in either cholesterol or urine PCR (figure 3B).

DISCUSSION

We have examined the lung function response to rapamycin and related side effects in a prospective national cohort of women with progressive lung disease due to LAM. Overall, rapamycin was associated with reduced disease progression, but a significant minority continued to lose lung function at an accelerated rate. While side effects were common, particularly at higher doses of rapamycin, they did not require cessation of therapy and remained at tolerable levels over several years. Likewise, elevations in serum cholesterol and proteinuria were small and manageable.

In all cases, treatment with rapamycin was associated with improvements in ΔFEV_1 . In this study, the mean ΔFEV_1 observed for almost 3 years of treatment was +11 mL/year and similar to that observed over shorter periods and in other cohorts.^{5 14} What is striking is the variability in post-treatment ΔFEV_1 , which, although observed in other studies, has not been previously addressed. Those with the most favourable values of ΔFEV_1 tended to have had LAM for less time and had better lung function, particularly FEV_1 , at the start of treatment. Importantly, this favourable lung function response was not simply accounted for by higher rapamycin levels in this group. It is possible that those with the least response to rapamycin have disease that is less dependent on mTOR dysregulation as suggested by the finding that signalling pathways other than mTOR contribute to tumourigenesis in LAM cells.²⁰ In addition, VEGF-D is synthesised by LAM cells and is a transcriptional target of mTOR: the finding that higher levels of serum VEGF-D are associated with a better response to rapamycin is potentially consistent with differing levels of mTOR dysregulation and influence on the disease phenotype between individuals.²¹ Conversely, resistance to rapamycin may be acquired over time as occurs in breast cancer cells in vitro²²; with potential mechanisms including cellular efflux of rapamycin by ATP-binding cassette transporters, mutations in rapamycin-binding proteins, including FKBP, or loss of function or feedback in pathways such as Akt and retinoblastoma protein mediating some rapamycin-dependent growth effects.^{23 24} It is also possible that, in more advanced disease, LAM-related tissue remodelling itself, including recruitment of wild-type cells, can support LAM nodule growth and lung destruction, independent of mTOR signalling.²⁵ LAM is variable both in severity and its clinical manifestations, and it is conceivable that specific LAM phenotypes or groups of clinical features may be associated with favourable or unfavourable responses to rapamycin. The finding that those with the most and least favourable responses had different pretreatment characteristics but that these characteristics were not significant in across the group as a whole suggests that those with good or poor responses to mTOR inhibition have different phenotypes or drug sensitivity rather than all patients being part of a continuous




Figure 3 Effect of rapamycin on serum cholesterol and urine protein. (A) Mean and SE of plasma cholesterol and urine PCR during treatment. (B) Association of serum rapamycin level with serum cholesterol and urine PCR after 1 year of therapy. PCR, protein:creatinine ratio.

spectrum of rapamycin responsiveness, although larger prospective studies will be required to address this point definitively. Previous reports have suggested that those with chyloous complications respond well to rapamycin,¹¹ and although in our study, those with positive values of ΔFEV_1 had more lymphatic disease than those with negative ΔFEV_1 values, this was not significantly different overall. It is possible that the benefit obtained from rapamycin in lymphatic remodelling leading to reductions in lymphatic masses and chyloous collections does not translate into longer-term effects on lung parenchymal damage. However, our study was not powered to definitively assess the association of individual or groups of clinical features and treatment response.

We were interested to observe that there was no association between ΔFEV_1 and serum rapamycin level. Although there was a weak association between serum rapamycin level and lower FEV_1 at the start of therapy, we cannot completely exclude the possibility that the lack of a dose–response relationship was due to this, although the level of difference is unlikely to have influenced the findings significantly. Our findings would be consistent with the idea that serum levels greater than 2 pg/mL are sufficient to treat progressive lung disease in most women with LAM. While most clinical trials of rapamycin showing benefits on lung function and angiomyolipoma have titrated serum levels to 5–10 pg/mL, a retrospective study has suggested that lower serum rapamycin levels may be equally effective.²⁶ Our study, examining the group as a whole, was unable to assess if there was a dose–response relationship between rapamycin level and ΔFEV_1 for individual subjects; however, this study would require very long periods of observation and has not yet been performed.

Side effects were common and tended to occur either at the start of treatment and reduce over time (mouth ulcers, nausea and diarrhoea) or some weeks into treatment and persist (acne, oedema, menstrual disturbance). In excess of 1 year of treatment, individual side effects occurred in less than 5% of individuals

overall. Unlike lung function response, there was a relationship between side effects and serum rapamycin levels with mean serum level positively associated with the six most common side effects over 1 year with nausea and diarrhoea particularly increasing at higher serum levels. Changes in laboratory indices mainly comprised a persistent elevation in serum cholesterol and transient proteinuria but in no individuals resulted in the need to stop therapy. There was no clear correlation between rapamycin level and elevation in either urinary protein or serum cholesterol.

Our study was a real-world observational cohort of those receiving rapamycin for progressive lung disease. As the Centre provides care for over two-thirds of the UK population with a range of ages, clinical phenotypes and severity, the study benefited from being an unselected group representative of the disease as a whole.¹⁵ Subjects were treated according to a standard protocol and seen at all visits by the same clinical team and had lung function measured at the same centre. However, various limitations are inherent real-world cohorts, side effect reporting relied on patient recall and treatment duration was not the same for all participants. As a consequence, extremes of ΔFEV_1 where values exceeded 100 mL/year in either direction tended to be those with a duration of observation of less than 3 years, suggesting that some of this variability may be attributed to shorter-term variation or regression to the mean.¹⁹ However, even in those treated for longer periods, there was still significant variability in response. As rapamycin has become the standard of care from those with progressive lung disease, it is no longer possible to study untreated control subjects matched for disease severity. However, these subjects had similar overall levels of base line lung function, lung function response and side effects seen in other studies including the Multicenter International Lymphangiomyomatosis Efficacy of Sirolimus (MILES) trial, a 1-year randomised placebo controlled trial of rapamycin.^{5 14}

Although serum rapamycin level and baseline lung function were not examined in the MILES trial, MILES has been the only other study to examine variability in response to rapamycin where a poorer response over 1 year was associated with low baseline serum VEGF-D values, perhaps consistent with less-mTOR-dependent disease.^{5 21}

Our findings have clinical implications and suggest that lower serum rapamycin levels are associated with fewer side effects but no reduction in efficacy with potential benefits in reduced long-term toxicity and costs. The observation that better responses were associated with earlier disease is consistent with the idea that early intervention with low-dose rapamycin may be the best way to preserve lung function. The decision on when to offer treatment with rapamycin to balance preservation of lung function against cumulative side effects, and indeed the risk of unnecessary treatment of some individuals, is a critical issue for physicians and women with LAM. The recent ATS/Japanese Respiratory Society statement recommends the introduction of treatment for those with FEV₁ or DL_{CO} <70% of the predicted value.¹² It is currently not known how best to identify those with active disease earlier in their natural history. Those with active disease may include those with falling FEV₁ while still in the normal range, those with normal spirometry but impaired DL_{CO} or exertional hypoxaemia. In addition, higher levels of VEGF-D and younger age at presentation are more likely to indicate active disease and benefit from early treatment. The use of lower doses of rapamycin than previously studied with the aim of preserving lung function in early disease is to be tested in a randomised clinical trial (ClinicalTrials.gov Identifier: NCT03150914). It is also important to recognise that some treated with rapamycin continue to lose lung function at an accelerated rate, and a formal study of disease phenotypes associated with poor lung function response and a protocol considering adjunctive therapy to rapamycin would improve management of individuals with aggressive and less mTOR inhibitor responsive disease, although this would require international collaboration.

Contributors SRJ conceived the study. SRJ and SF saw all participants. JB, SF, SM and SRJ recorded and analysed the data. All authors contributed to the final manuscript.

Competing interests None declared.

Patient consent Detail has been removed from this case description/these case descriptions to ensure anonymity. The editors and reviewers have seen the detailed information available and are satisfied that the information backs up the case the authors are making.

Ethics approval East Midlands Research Ethics Committee (13/EM/0264).

Provenance and peer review Not commissioned; externally peer reviewed.

© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

REFERENCES

- Johnson SR, Taveira-DaSilva AM, Moss J. Lymphangioleiomyomatosis. *Clin Chest Med* 2016;37:389–403.
- Harknett EC, Chang WYC, Byrnes S, *et al.* Regional and national variability suggests underestimation of prevalence of Lymphangioleiomyomatosis. *Q J Med* 2011;104:971–9.
- Finlay G. The LAM cell: what is it, where does it come from, and why does it grow? *Am J Physiol Lung Cell Mol Physiol* 2004;286:690L–3.
- Lam HC, Nijmeh J, Henske EP. New developments in the genetics and pathogenesis of tumours in tuberous sclerosis complex. *J Pathol* 2017;241:219–25.
- McCormack FX, Inoue Y, Moss J, *et al.* Efficacy and safety of sirolimus in lymphangioleiomyomatosis. *N Engl J Med* 2011;364:1595–606.
- Goldberg HJ, Harari S, Cottin V, *et al.* Everolimus for the treatment of lymphangioleiomyomatosis: a phase II study. *Eur Respir J* 2015;46:783–94.
- Takada T, Mikami A, Kitamura N, *et al.* Efficacy and safety of long-term Sirolimus therapy for Asian patients with Lymphangioleiomyomatosis. *Ann Am Thorac Soc* 2016;13:1912–22.
- Bissler JJ, McCormack FX, Young LR, *et al.* Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. *N Engl J Med* 2008;358:140–51.
- Davies DM, de Vries PJ, Johnson SR, *et al.* Sirolimus therapy for angiomyolipoma in tuberous sclerosis and sporadic lymphangioleiomyomatosis: a phase 2 trial. *Clin Cancer Res* 2011;17:4071–81.
- Bissler JJ, Kingswood JC, Radzikowska E, *et al.* Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial. *Lancet* 2013;381:817–24.
- Taveira-DaSilva AM, Hathaway O, Stylianou M, *et al.* Changes in lung function and chylous effusions in patients with lymphangioleiomyomatosis treated with sirolimus. *Ann Intern Med* 2011;154:797–805.
- McCormack FX, Gupta N, Finlay GR, *et al.* Official American thoracic society/Japanese respiratory society clinical practice guidelines: lymphangioleiomyomatosis diagnosis and management. *Am J Respir Crit Care Med* 2016;194:748–61.
- Krueger DA, Northrup H. International Tuberous Sclerosis Complex Consensus Group. Tuberous sclerosis complex surveillance and management: recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference. *Pediatr Neurol* 2013;49:255–65.
- Yao J, Taveira-DaSilva AM, Jones AM, *et al.* Sustained effects of sirolimus on lung function and cystic lung lesions in lymphangioleiomyomatosis. *Am J Respir Crit Care Med* 2014;190:1273–82.
- Bee J, Bhatt R, McCafferty I, *et al.* A 4-year prospective evaluation of protocols to improve clinical outcomes for patients with lymphangioleiomyomatosis in a national clinical centre. *Thorax* 2015;70:1202–4.
- Sasongko TH, Ismail NF, Zabidi-Hussin Z. Rapamycin and rapalogs for tuberous sclerosis complex. *Cochrane Database Syst Rev* 2016;7:CD011272.
- Miller MR, Crapo R, Hankinson J, *et al.* General considerations for lung function testing. *Eur Respir J* 2005;26:153–61.
- Quanjer PH, Tammeling GJ, Cotes JE, *et al.* Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society. *Eur Respir J Suppl* 1993;16:5–40.
- Johnson SR, Tattersfield AE. Decline in lung function in lymphangioleiomyomatosis: relation to menopause and progesterone treatment. *Am J Respir Crit Care Med* 1999;160:628–33.
- D'Armiento J, Shiomi T, Marks S, *et al.* Mesenchymal tumorigenesis driven by TSC2 haploinsufficiency requires HMGA2 and is independent of mTOR pathway activation. *Cancer Res* 2016;76:844–54.
- Young L, Lee HS, Inoue Y, *et al.* Serum VEGF-D a concentration as a biomarker of lymphangioleiomyomatosis severity and treatment response: a prospective analysis of the Multicenter International Lymphangioleiomyomatosis Efficacy of Sirolimus (MILES) trial. *Lancet Respir Med* 2013;1:445–52.
- Noh WC, Mondesire WH, Peng J, *et al.* Determinants of rapamycin sensitivity in breast cancer cells. *Clin Cancer Res* 2004;10:1013–23.
- Sabatini DM. mTOR and cancer: insights into a complex relationship. *Nat Rev Cancer* 2006;6:729–34.
- Kurmasheva RT, Huang S, Houghton PJ. Predicted mechanisms of resistance to mTOR inhibitors. *Br J Cancer* 2006;95:955–60.
- Clements D, Dongre A, Krymskaya VP, *et al.* Wild type mesenchymal cells contribute to the lung pathology of lymphangioleiomyomatosis. *PLoS One* 2015;10:e0126025.
- Ando K, Kurihara M, Kataoka H, *et al.* Efficacy and safety of low-dose sirolimus for treatment of lymphangioleiomyomatosis. *Respir Investig* 2013;51:175–83.